Home › NDC Lookup › Ingredients › Colestipol Hydrochloride › 70710-1467-07
Colestipol hydrochloride 1 g Tablet, Film Coated, Bottle of 120 — NDC 70710-1467-07 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 70710-1467-07: Colestipol hydrochloride 1 g Tablet, Film Coated, Bottle of 120

by Zydus Pharmaceuticals USA Inc.

This is a package of 120 tablets of Colestipol hydrochloride 1 g Tablet, Film Coated from Zydus Pharmaceuticals USA Inc., first listed with the FDA May 2022 and currently FDA-listed; retail pharmacies pay about $0.6622 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

🏷️ FDA NDC (as labeled) 70710-1467-7 billing pads the package segment with a zero
This package
Contains120-count Cost per ea$0.6622 NADAC Per package$79.46 / 120 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.5615/unit — full pricing hub ↓
Main listing for product 70710-1467 · Also comes in: 500 tablets 70710-1467-5
Rx only Generic FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Oct 15, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 70710-1467-7 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
70710 labeler · 1467 product · 7 package
Package marketed since
May 4, 2022
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
120 EA per package
Barcode (UPC)
0370710146771
Medicaid fills, this package
29,116 prescriptions in the last four reported quarters
FDA record last changed
Oct 15, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70710-1467-7
Product NDC 70710-1467
11-digit billing NDC 70710146707
NCPDP billing unit EA — each (per item)
RxCUI 1048445
UNII X7D10K905G
UPC 0370710146771
Application # ANDA215223
SPL Set ID 71f12e0d-373a-4867-b37c-f24d99c5ce95
Established class (EPC) Bile Acid Sequestrant
Mechanism of action Bile-acid Binding Activity
DEA schedule Non-controlled
Marketing category ANDA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2022-05-04
Route ORAL
Dosage form TABLET, FILM COATED
Substance COLESTIPOL HYDROCHLORIDE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 39100020100320
GPI class Colestipol HCl
GCN Seq No 022344
GCN 25442
HICL code 001374
Ingredient (HICL) Colestipol Hcl
HIC1 code D
Therapeutic class — broad (HIC1) Biliary System/Gastro-Intestinal System
HIC2 code D7
Therapeutic class — intermediate (HIC2) Act Primarily On Liver/Biliary Tract
HIC3 code D7L
Therapeutic class — specific (HIC3) Bile Salt Sequestrants
AHFS code 24:06.04.00
AHFS class Bile Acid Sequestrants
FDB label name COLESTIPOL HCL 1 GM TABLET
FDB brand name Colestipol Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 022344
  • GCN: 25442
  • GPI-14 (Medi-Span): 39100020100320
  • HICL (First Databank): 001374
  • AHFS class code: 24:06.04.00
  • RxCUI (RxNorm): 1048445
Why two NDCs? The FDA registers this code as 70710-1467-7 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70710-1467-07. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Bile Acid Sequestrant class.

Pharmacologic class Bile Acid Sequestrant
Drug family (ATC) Bile acid sequestrants
How it works Bile-acid Binding Activity
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name COLESTIPOL HCL 1 GM TABLET Ingredient Colestipol Hcl
📖 What it is MedlinePlus · NLM

Colestipol is used to decrease the amount of cholesterol (a fat-like substance that can build up in blood vessels leading to heart attack or strokes or other medical conditions). Colestipol is in a class of medications called bile acid sequestrants. It works by binding bile acids in your intestines to form a product that is removed from the body.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It lowers LDL and total cholesterol when diet alone hasn't done enough. It works alongside a cholesterol-lowering diet, not instead of one. It usually doesn't lower triglycerides.
  • Tablets go down whole, one at a time, with plenty of liquid, and shouldn't be cut, crushed or chewed. Granules or powder must always be mixed with water or another fluid, never tak...
  • Colestipol can bind other drugs in your gut and keep them from being absorbed. Take your other medicines at least 1 hour before or 4 hours after colestipol. Ask me if you're unsure...
  • Why do I need to space colestipol from my other medicines?
📖 Read our full Colestipol guide →
8
Nutrient depletion considerations

Colestipol may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.662 $79.46 / 120 tablets
Medicaid paysCMS SDUD · 12 mo $0.5615 $67.38 / 120 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2024 Jul 2025 Mar 2026 Nov 2026 $0.719 $0.631
▲ Up 3% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
70710-1467-05 70710-1467-5 500 TABLET, FILM COATED in 1 BOTTLE — — 2022-05-04 — Active
70710-1467-07 You're viewing this Main listing 120 TABLET, FILM COATED in 1 BOTTLE $0.6622 / ea $79.46 2022-05-04 — Active

You're viewing the smallest of 2 pack sizes for this product.

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 120-count package — 120 tablet, film coated in 1 bottle.
How does this package differ from NDC 70710-1467-05?
Both are Colestipol hydrochloride 1 g Tablet, Film Coated — the drug itself is identical. This page's package is the 120-count one, while NDC 70710-1467-05 is the 500 tablets package.
What NDC number is used to bill for this package of Colestipol hydrochloride 1 g Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Colestipol Hydrochloride 1 g 42799-0115-01 Edenbridge 120 tablets $0.662 AB Availability likely —
Colestipol Hydrochloride 1 g 50742-0284-12 Ingenus 120 tablets $0.662 AB Availability likely —
Colestipol Hydrochloride 1 g 59762-0450-01 Mylan 120 tablets $0.662 AB Availability likely —
Colestipol Hydrochloride 1 g 60687-0715-21 American 1 tablet $0.662 AB Availability likely —
Colestipol Hydrochloride 1 g 62559-0395-12 ANI 120 tablets $0.662 AB Availability likely —
Colestipol hydrochloride 1 gthis 70710-1467-07 Zydus 120 tablets $0.662 AB Availability likely —
Colestipol Hydrochloride 1 g 72603-0817-01 NorthStar 120 tablets $0.662 AB Availability likely —
Colestid 1 g 00009-0450-03 Pharmacia 120 tablets $2.146 AB FDA listed +224%
Colestipol Hydrochloride 1 g 00115-5211-02 Amneal 500 tablets — AB FDA listed —
Colestipol hydrochloride 1 g 70771-1653-05 Zydus 500 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
Listed with the FDA since
May 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
This is a generic
listed with the FDA
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color Yellow
ShapeOval
ImprintCZ
Size20 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Colestipol inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII F2O5O2OI9F
    A cellulose derivative made by chemically modifying plant fiber. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in the digestive system.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 2S7830E561
    Crospovidone is a synthetic polymer derived from povidone. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the active ingredient can be absorbed.
  • UNII EX438O2MRT
    Ferric oxide yellow is a naturally occurring iron compound used as a colorant in medications. It gives tablets, capsules, and other forms a yellow or golden hue for identification and appearance.
  • UNII 3NXW29V3WO
    Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII 532B59J990
    Polyvinyl alcohol is a synthetic polymer made from plant-derived materials. It's used as a binder to hold ingredients together, a film-former in coatings, and a thickener in liquid formulations.
  • UNII FZ989GH94E
    Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII XHX3C3X673
    Triacetin is a clear, oily liquid made from glycerin and acetic acid. It works as a plasticizer and solvent in medicines, helping soften coatings and improve how liquids mix together in formulations.

10 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerZydus Pharmaceuticals USA Inc.
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA215223 (ANDA)
Labeler code70710
First marketedMay 2022
Product typeHuman Prescription Drug
Portfolio456 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ~1 min read ▾

INDICATIONS AND USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients.

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy.

Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy.

The NCEP treatment guidelines are shown below. * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 45 years; female: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥ 60 mg/dL (1.6 mmol/L). LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease * Two or More Other Risk Factors ** Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 (≥ 3.4) ≤ 100 (≤ 2.6)

⏱️ Dosage and Administration ~1 min read ▾

DOSAGE AND ADMINISTRATION For adults, colestipol hydrochloride tablets are recommended in doses of 2 grams/day to 16 grams/day given once or in divided doses. The starting dose should be 2 grams once or twice daily. Dosage increases of 2 grams, once or twice daily should occur at 1 month or 2 month intervals.

Appropriate use of lipid profiles as per NCEP guidelines including LDL-C and triglycerides, is advised so that optimal but not excessive doses are used to obtain the desired therapeutic effect on LDL-C level. If the desired therapeutic effect is not obtained at a dose of 2 grams/day to 16 grams/day with good compliance and acceptable side effects, combined therapy or alternate treatment should be considered. Colestipol hydrochloride tablets must be taken one at a time and be promptly swallowed whole, using plenty of water or other appropriate liquid.

Do not cut, crush or chew the tablets. Patients should take other drugs at least one hour before or four hours after colestipol hydrochloride tablets to minimize possible interference with their absorption. (See Drug Interactions .) Before Administration of Colestipol Hydrochloride Tablets Define the type of hyperlipoproteinemia, as described in NCEP guidelines.

Institute a trial of diet and weight reduction. Establish baseline serum total and LDL-C and triglyceride levels. During Administration of Colestipol Hydrochloride Tablets The patient should be carefully monitored clinically, including serum cholesterol and triglyceride levels.

Periodic determinations of serum cholesterol levels as outlined in the NCEP guidelines should be done to confirm a favorable initial and long-term response. Failure of total or LDL-C to fall within the desired range should lead one to first examine dietary and drug compliance. If these are deemed acceptable, combined therapy or alternate treatment should be considered.

Significant rise in triglyceride level should be considered as indication for dose reduction, drug discontinuation or combined or alternate therapy.

⛔ Contraindications 18 words ▾

CONTRAINDICATIONS Colestipol hydrochloride tablets are contraindicated in those individuals who have shown hypersensitivity to any of their components.

🤒 Adverse Reactions ~2 min read ▾

ADVERSE REACTIONS Gastrointestinal The most common adverse reactions are confined to the gastrointestinal tract. To achieve minimal GI disturbance with an optimal LDL-C lowering effect, a gradual increase of dosage starting with 2 grams, once or twice daily is recommended. Constipation is the major single complaint and at times is severe.

Most instances of constipation are mild, transient and controlled with standard treatment. Increased fluid intake and inclusion of additional dietary fiber should be the first step; a stool softener may be added if needed. Some patients require decreased dosage or discontinuation of therapy.

Hemorrhoids may be aggravated. Other, less frequent gastrointestinal complaints consist of abdominal discomfort (abdominal pain and cramping), intestinal gas (bloating and flatulence), indigestion and heartburn, diarrhea and loose stools and nausea and vomiting. Bleeding hemorrhoids and blood in the stool have been infrequently reported.

Peptic ulceration, cholecystitis and cholelithiasis have been rarely reported in patients receiving COLESTID granules and are not necessarily drug related. Difficulty swallowing and transient esophageal obstruction have been rarely reported in patients taking colestipol hydrochloride tablets. Transient and modest elevations of aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) and alkaline phosphatase were observed on one or more occasions in various patients treated with colestipol hydrochloride.

The following nongastrointestinal adverse reactions have been reported with generally equal frequency in patients receiving colestipol hydrochloride tablets, COLESTID granules or placebo in clinical studies: Cardiovascular Chest pain, angina and tachycardia have been infrequently reported. Hypersensitivity Rash has been infrequently reported. Urticaria and dermatitis have been rarely noted in patients receiving COLESTID granules.

Musculoskeletal Musculoskeletal pain, aches and pains in the extremities, joint pain and arthritis and backache have been reported. Neurologic Headache, migraine headache and sinus headache have been reported. Other infrequently reported complaints include dizziness, light-headedness and insomnia.

Miscellaneous Anorexia, fatigue, weakness, shortness of breath and swelling of the hands or feet, have been infrequently reported. To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc., at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🔄 Drug Interactions ~2 min read ▾

Drug Interactions Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids. In vitro studies have indicated that colestipol hydrochloride binds a number of drugs. Therefore, colestipol hydrochloride tablets may delay or reduce the absorption of concomitant oral medication.

The interval between the administration of colestipol hydrochloride tablets and any other medication should be as long as possible. Patients should take other drugs at least one hour before or four hours after colestipol hydrochloride tablets to avoid impeding their absorption. Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.

However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption; the time to reach maximum concentration was delayed approximately 30 minutes. Effects on the absorption of other beta-blockers have not been determined. Therefore, patients on propranolol should be observed when colestipol hydrochloride tablets are either added or deleted from a therapeutic regimen.

Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride. The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride; these drugs were not tested to determine the effect of administration one hour before colestipol hydrochloride. No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.

Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin. The potential for binding of these drugs if given concomitantly is present. Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.

Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone. A study has shown that cholestyramine binds bile acids and reduces mycophenolic acid exposure. As colestipol also binds bile acids, colestipol may reduce mycophenolic acid exposure and potentially reduce efficacy of mycophenolate mofetil.

🧒 Pediatric Use 13 words ▾

Pediatric Use Safety and effectiveness in the pediatric population have not been established.

🆘 Overdosage 47 words ▾

OVERDOSAGE Overdosage of colestipol hydrochloride tablets has not been reported. Should overdosage occur, however, the chief potential harm would be obstruction of the gastrointestinal tract. The location of such potential obstruction, the degree of obstruction and the presence or absence of normal gut motility would determine treatment.

🧬 Clinical Pharmacology ~3 min read ▾

CLINICAL PHARMACOLOGY Cholesterol is the major and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating absorption.

A major portion of the bile acids secreted is reabsorbed from the intestines and returned via the portal circulation to the liver, thus completing the enterohepatic cycle. Only very small amounts of bile acids are found in normal serum. Colestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces.

This nonsystemic action results in a partial removal of the bile acids from the enterohepatic circulation, preventing their reabsorption. Since colestipol hydrochloride is an anion exchange resin, the chloride anions of the resin can be replaced by other anions, usually those with a greater affinity for the resin than the chloride ion. Colestipol hydrochloride is hydrophilic, but it is virtually water insoluble (99.75%) and it is not hydrolyzed by digestive enzymes.

The high molecular weight polymer in colestipol hydrochloride apparently is not absorbed. In humans, less than 0.17% of a single 14 C-labeled colestipol hydrochloride dose is excreted in the urine when given following 60 days of dosing of 20 grams of colestipol hydrochloride per day. The increased fecal loss of bile acids due to colestipol hydrochloride administration leads to an increased oxidation of cholesterol to bile acids.

This results in an increase in the number of low-density lipoprotein (LDL) receptors, increased hepatic uptake of LDL and a decrease in beta lipoprotein or LDL serum levels and a decrease in serum cholesterol levels. Although colestipol hydrochloride produces an increase in the hepatic synthesis of cholesterol in man, serum cholesterol levels fall. There is evidence to show that this fall in cholesterol is secondary to an increased rate of clearance of cholesterol-rich lipoproteins (beta or low-density lipoproteins) from the plasma.

Serum triglyceride levels may increase or remain unchanged in colestipol hydrochloride treated patients. The decline in serum cholesterol levels with colestipol hydrochloride treatment is usually evident by one month. When colestipol hydrochloride is discontinued, serum cholesterol levels usually return to baseline levels within one month.

Periodic determinations of serum cholesterol levels as outlined in the National Cholesterol Education Program (NCEP) guidelines, should be done to confirm a favorable initial and long-term response. 1 In a large, placebo-controlled, multiclinic study, the LRC-CPPT 2 , hypercholesterolemic subjects treated with cholestyramine, a bile-acid sequestrant with a mechanism of action and an effect on serum cholesterol similar to that of colestipol hydrochloride, had reductions in total and LDL-C. Over the 7 year study period the cholestyramine group experienced a 19% reduction (relative to the incidence in the placebo group) in the combined rate of coronary heart disease (CHD) death plus nonfatal myocardial infarction (cumulative incidences of 7% cholestyramine and 8.6% placebo).

The subjects included in the study were middle-aged men (aged 35 to 59) with serum cholesterol levels above 265 mg/dL, LDL-C above 175 mg/dL on a moderate cholesterol-lowering diet and no history of heart disease. It is not clear to what extent these findings can be extrapolated to other segments of the hypercholesterolemic population not studied. Treatment with colestipol results in a significant increase in lipoprotein LpAI.

Lipoprotein LpAI is one of the two major lipoprotein particles within the high-density lipoprotein (HDL) density range 3 and has been shown in cell culture to promote cholesterol efflux or removal from cells 4 . Although the significance of this finding has not been established in clinical studies, the elevation of the lipoprotein LpAI particle withi… [Excerpted — this section continues on DailyMed.]

📦 How Supplied / Storage and Handling 76 words ▾

HOW SUPPLIED Colestipol hydrochloride tablets, 1 g are light yellow to yellow colored, oval shaped, biconvex, film-coated tablets, one side debossed with "CZ" and plain on the other side and are supplied as follows: NDC 70710-1467-7 in bottles of 120 tablets with child-resistant closure. NDC 70710-1467-5 in bottles of 500 tablets Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Protect from moisture.

📋 Description 112 words ▾

DESCRIPTION The active ingredient in colestipol hydrochloride tablets is colestipol hydrochloride, which is a lipid lowering agent for oral use. Colestipol is an insoluble, high molecular weight basic anion-exchange copolymer of diethylenetriamine and 1-chloro-2,3-epoxpropane (hydrochloride), with approximately one out of five amine nitrogens protonated. It is a yellow to orange powder or beads water-insoluble resin which is hygroscopic and swells when suspended in water or aqueous fluids.

Each colestipol hydrochloride tablet contains one gram of colestipol hydrochloride. Colestipol hydrochloride tablets are light yellow to yellow in color and are tasteless and odorless. Inactive ingredients: cellacefate, colloidal silicon dioxide, crospovidone, ferric oxide yellow, hypromellose, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, povidone, and triacetin.

💬 Information for Patients 194 words ▾

Information for Patients Colestipol hydrochloride tablets may be larger than pills you have taken before. If you have had swallowing problems or choking with food, liquids or other tablets or capsules in the past, you should discuss this with your doctor before taking colestipol hydrochloride tablets. It is important that you take colestipol hydrochloride tablets correctly: Always take one tablet at a time and swallow promptly.

Swallow each tablet whole. Do not cut, crush or chew the tablets. Colestipol hydrochloride tablets must be taken with water or another liquid that you prefer.

Swallowing the tablets will be easier if you drink plenty of liquid as you swallow each tablet. Difficulty swallowing and temporary obstruction of the esophagus (the tube between your mouth and stomach) have been rarely reported in patients taking colestipol hydrochloride tablets. If a tablet does get stuck after you swallow it, you may notice pressure or discomfort.

If this happens to you, you should contact your doctor. Do not take colestipol hydrochloride tablets again without your doctor's advice. If you are taking other medications, you should take them at least one hour before or four hours after taking colestipol hydrochloride tablets.

⚠️ Precautions ~3 min read ▾

PRECAUTIONS Prior to initiating therapy with colestipol hydrochloride tablets, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (< 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(Triglycerides/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation.

In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases colestipol hydrochloride tablets may not be indicated. Because it sequesters bile acids, colestipol hydrochloride may interfere with normal fat absorption and, thus, may reduce absorption of folic acid and fat soluble vitamins such as A, D and K.

Chronic use of colestipol hydrochloride may be associated with an increased bleeding tendency due to hypoprothrombinemia from vitamin K deficiency. This will usually respond promptly to parenteral vitamin K 1 and recurrences can be prevented by oral administration of vitamin K 1 . Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm a favorable initial and adequate long-term response.

Colestipol hydrochloride tablets may produce or severely worsen pre-existing constipation. The dosage should be increased gradually in patients to minimize the risk of developing fecal impaction. In patients with pre-existing constipation, the starting dose should be 2 grams once or twice a day.

Increased fluid and fiber intake should be encouraged to alleviate constipation and a stool softener may occasionally be indicated. If the initial dose is well tolerated, the dose may be increased as needed by a further 2 grams/day to 4 grams/day (at monthly intervals) with periodic monitoring of serum lipoproteins. If constipation worsens or the desired therapeutic response is not achieved at 2 grams/day to 16 grams/day, combination therapy or alternate therapy should be considered.

Particular effort should be made to avoid constipation in patients with symptomatic coronary artery disease. Constipation associated with colestipol hydrochloride tablets may aggravate hemorrhoids. While there have been no reports of hypothyroidism induced in individuals with normal thyroid function, the theoretical possibility exists, particularly in patients with limited thyroid reserve.

Since colestipol hydrochloride is a chloride form of an anion exchange resin, there is a possibility that prolonged use may lead to the development of hyperchloremia acidosis. Carcinogenesis, Mutagenesis and Impairment of Fertility In studies conducted in rats in which cholestyramine resin (a bile acid sequestering agent similar to colestipol hydrochloride) was used as a tool to investigate the role of various intestinal factors, such as fat, bile salts and microbial flora, in the development of intestinal tumors induced by potent carcinogens, the incidence of such tumors was observed to be greater in cholestyramine resin treated rats than in control rats.

The relevance of this laboratory observation from studies in rats with cholestyramine resin to the clinical use of colestipol hydrochloride tablets is not known. In the LRC-CPPT study referred to above, the total incidence of fatal and nonfatal neoplasms was similar in both treatment groups. When the many different categories of tumors are examined, various alimentary system cancers were somewhat more prevalent in the cholestyramine group.

The small numbers and the multiple categories prevent conclusions from being drawn. Further follow-up of the LRC-CPPT participants by the sponsors of that study is planned for cause-specific mortality and cancer morbidity. When colesti… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 35 words ▾

Nursing Mothers Caution should be exercised when colestipol hydrochloride tablets are administered to a nursing mother. The possible lack of proper vitamin absorption described in the "Pregnancy" section may have an effect on nursing infants.

📚 References ~1 min read ▾

REFERENCES Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269(23):3015– 3023. Lipid Metabolism-Atherogenesis Branch, National Heart, Lung, and Blood Institute, Bethesda, MD: The Lipid Research Clinics Coronary Primary Prevention Trial Results.

I. Reduction in Incidence of Coronary Heart Disease. JAMA 1984; 251:351–364.

Parra HJ, et al. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin.

Chem. 1990; 36(8):1431–1435. Barbaras R, et al.

Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem. Biophys.

Res. Comm. 1987; 142(1):63–69.

Kane JP, et al. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl.

J. Med. 1981; 304:251–258.

Illingworth DR, et al. Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolemia. Lancet 1981; 1:296–298.

Kuo PT, et al. Familial type II hyperlipoproteinemia with coronary heart disease: Effect of diet-colestipol-nicotinic acid treatment. Chest 1981; 79:286–291.

Blankenhorn DH, et al. Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts. JAMA 1987; 257(23):3233–3240.

Cashin-Hemphill L, et al. Beneficial Effects of Colestipol-Niacin on Coronary Atherosclerosis: A 4-Year Follow-up. JAMA 1990; 264:3013–3017.

Brown G. et al. Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B. N.

Engl.J. Med. 1990; 323:1289–1298.

Kane JP, et al. Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia with Combined Drug Regimens. JAMA 1990; 264:3007–3012.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. The brand listed are trademarks of their respective owners.

📄 Package Label / Principal Display Panel 17 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Colestipol hydrochloride tablets, 1 g 120 tablets NDC 70710-1467-7 Rx only Zydus image

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
29.1K
Units reimbursed last 4 qtrs
2.8M
Gross reimbursed last 4 qtrs
$1.57M
Avg / prescription
$54.04
Avg / unit
$0.5615
Latest quarter Q1 2026
6.8KRx
Medicaid pays / ea
$0.5615
gross reimbursed
vs
NADAC / ea
$0.6622
acquisition cost
=
Spread
−$0.1007
-15% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
34% FFS 66% MCO
Fee-for-service · 9,802 Rx Managed care · 19,314 Rx
State Medicaid map
Alaska: 6,240 units · 851 per 100k residents AK Maine: 23,288 units · 1,669 per 100k residents ME Washington: 56,186 units · 719 per 100k residents WA Idaho: 22,018 units · 1,121 per 100k residents ID Montana: 12,364 units · 1,092 per 100k residents MT North Dakota: no data reported ND Minnesota: 57,136 units · 996 per 100k residents MN Wisconsin: 101,190 units · 1,712 per 100k residents WI Michigan: 103,965 units · 1,036 per 100k residents MI New York: 94,944 units · 485 per 100k residents NY Vermont: no data reported VT New Hampshire: 10,736 units · 766 per 100k residents NH Oregon: 55,364 units · 1,308 per 100k residents OR Nevada: 20,129 units · 630 per 100k residents NV Wyoming: no data reported WY South Dakota: 3,240 units · 353 per 100k residents SD Iowa: 55,028 units · 1,716 per 100k residents IA Illinois: 15,469 units · 123 per 100k residents IL Indiana: 41,288 units · 602 per 100k residents IN Ohio: 309,501 units · 2,626 per 100k residents OH Pennsylvania: 169,024 units · 1,304 per 100k residents PA New Jersey: 17,337 units · 187 per 100k residents NJ Massachusetts: 25,394 units · 363 per 100k residents MA California: 48,537 units · 125 per 100k residents CA Utah: 35,129 units · 1,028 per 100k residents UT Colorado: 83,847 units · 1,426 per 100k residents CO Nebraska: 43,888 units · 2,219 per 100k residents NE Missouri: 152,032 units · 2,454 per 100k residents MO Kentucky: 279,363 units · 6,172 per 100k residents KY West Virginia: 66,426 units · 3,753 per 100k residents WV Virginia: 99,833 units · 1,145 per 100k residents VA Maryland: 30,513 units · 494 per 100k residents MD Connecticut: 19,680 units · 544 per 100k residents CT Rhode Island: 4,710 units · 430 per 100k residents RI Arizona: 67,164 units · 904 per 100k residents AZ New Mexico: 13,320 units · 630 per 100k residents NM Kansas: 34,378 units · 1,169 per 100k residents KS Arkansas: 42,689 units · 1,392 per 100k residents AR Tennessee: 55,909 units · 785 per 100k residents TN North Carolina: 176,054 units · 1,625 per 100k residents NC South Carolina: 29,470 units · 548 per 100k residents SC Delaware: 3,690 units · 358 per 100k residents DE Oklahoma: 92,572 units · 2,284 per 100k residents OK Louisiana: 99,241 units · 2,170 per 100k residents LA Mississippi: 13,210 units · 449 per 100k residents MS Alabama: 25,969 units · 508 per 100k residents AL Georgia: 39,148 units · 355 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 21,996 units · 72.1 per 100k residents TX Florida: 23,388 units · 103 per 100k residents FL
Units reimbursed · per 100k residents
72.16,172
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 6,172 /100k
2 West Virginia 3,753 /100k
3 Ohio 2,626 /100k
4 Missouri 2,454 /100k
5 Oklahoma 2,284 /100k
6 Nebraska 2,219 /100k
7 Louisiana 2,170 /100k
8 Iowa 1,716 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
120 tablets this page70710-1467-07 29,433 Rx · $1,595,001
500 tablets70710-1467-05 No Medicaid data
Drug total (last 4 qtrs): 29,433 Rx · 2,839,367 units · $1,595,001 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Colestipol Hydrochloride — the ingredient across all brands.

Top reported reactions

Diarrhoea380
Nausea233
Fatigue220
Headache145
Vomiting128
Pain127
Weight Decreased116

Age at onset

Neonate1
Adolescent1
Adult196
Elderly210

Reporter sex

2,658 reports
Male · 31%
Female · 69%
Unknown · 0%

Serious outcomes

Hospitalization667
Death114
Life-threatening42
Disabling38
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 245 128
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.